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CSIC, Madrid, SpainCirculating microRNAs (miRNAs) have been proposed as type
2 diabetes biomarkers, and they may be a more sensitive way to
predict development of the disease than the currently used
tools. Our aim was to identify whether circulating miRNAs,
added to clinical and biochemical markers, yielded better po-
tential for predicting type 2 diabetes. The study included 462
non-diabetic patients at baseline in the CORDIOPREV study.
After a median follow-up of 60 months, 107 of them developed
type 2 diabetes. Plasma levels of 24 miRNAs were measured at
baseline by qRT-PCR, and other strong biomarkers to predict
diabetes were determined. The ROC analysis identiﬁed 9
miRNAs, which, added to HbA1c, have a greater predictive
value in early diagnosis of type 2 diabetes (AUC = 0.8342)
than HbA1c alone (AUC = 0.6950). The miRNA and HbA1c-
based model did not improve when the FINDRISC was
included (AUC = 0.8293). Cox regression analyses showed
that patients with low miR-103, miR-28-3p, miR-29a, and
miR-9 and high miR-30a-5p and miR-150 circulating levels
have a higher risk of disease (HR = 11.27; 95% CI = 2.61–
48.65). Our results suggest that circulating miRNAs could
potentially be used as a new tool for predicting the development
of type 2 diabetes in clinical practice.Received 17 November 2017; accepted 2 May 2018;
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During the last decade, the prevalence of type 2 diabetes mellitus
(T2DM) has been continuously on the rise; it has been estimated
that the current number of T2DM patients worldwide will double
in the next two decades1 and similar trends have been reported for
obesity.2 It is, therefore, critical that there be early identiﬁcation of
individuals at high risk for developing diabetes in order to devise pre-
vention strategies aimed at controlling the factors related to the devel-
opment of the disease.3,4146 Molecular Therapy: Nucleic Acids Vol. 12 September 2018 ª 2018
This is an open access article under the CC BY-NC-ND license (httpThe traditional biomarkers used to identify T2DM and pre-DM pa-
tients include glucose-homeostasis-related parameters, lipid classes,
and scores such as the Finnish Diabetes Risk Score (FINDRISC).5
In 2010, the American Diabetes Association (ADA) added glycated
hemoglobin (HbA1c) as a diagnostic criterion for diabetes and pre-
diabetes,6,7 due to the strong association with the high risk of devel-
oping the disease. The use of HbA1c as a diagnostic test certainly
has its advantages: convenience, less day-to-day variability, greater
pre-analytical stability, and international standardization. Moreover,
the FINDRISC has been successfully implemented as a practical
screening test to assess the risk of diabetes and detect undiagnosed
T2DM in European populations.8,9 However, these parameters and
tests also have their limitations and cannot precisely predict an indi-
vidual’s risk of developing T2DM, mainly because certain medical
conditions may affect HbA1c and cause falsely high or low read-
ings.10,11 In addition, previous studies have examined the perfor-
mance of HbA1c in comparison with fasting plasma glucose (FPG)
in diagnosis of dysglycemia in older adults, and the authors have
demonstrated considerable discrepancy between FPG- and HbA1c-
based diagnoses of T2DM and pre-T2DM, with differences accentu-
ated by race and gender.12,13 It has also been demonstrated that the
variability of HbA1c could be inﬂuenced by biological determinants
of hemoglobin glycation, including epidemiological, genetic, and
physiological factors.12The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgIt is, therefore, necessary to research into a new model that can use
both HbA1c and the new biomarkers to improve sensitivity and spec-
iﬁcity and increase the predictive value.
MicroRNAs (miRNAs) are autocrine and endocrine regulators of
gene expression. In the latter case, it has been demonstrated that
extracellular vesicles circulating in human plasma, which are a
mixture of microparticles, exosomes, and other structures such as
apoptotic bodies, contain miRNAs that can be considered as a novel
class of signaling molecules mediating intercellular communication.14
Some of these circulating miRNAs have been linked to glucose meta-
bolism,15 while others, such as miR-144, miR-146a, miR-150, miR-
182, miR-192, mir-29a, miR-30d, and miR-320, seem to participate
in the regulation of insulin signaling.16,17 There are others, too,
such as miR-375,18–21 miR-96,22 and miR-124a,23 which have been
associated with the development of T2DM and may also be involved
in its progression.24 One previous study has shown that a set of
miRNAs, including miR-15a, miR-29b, miR-126, miR-223, and
miR-28-3p, deregulated prior to the development of T2DM.25 How-
ever, this study lacks a reliable predictive value, since it was performed
in a reduced number of incident cases (n = 19), the T2DM diagnosis
was not performed according to all the ADA diagnosis criteria,26 and
a poor statistical analysis was conducted.25 Moreover, the idea about a
circulating miRNA proﬁle modulable by glucose homeostasis condi-
tions is supported by two other studies, which related miRNA plasma
levels with the grade of insulin resistance.27,28
Overall, there is evidence to suggest that a speciﬁc proﬁle of circu-
lating miRNAs could become a valuable biomarker to identify those
normoglycemic and prediabetic individuals at increased risk of devel-
oping T2DM. However, until now, no studies have been carried out in
a large population at high risk of developing T2DM to test this
hypothesis.
Based on this previous evidence, our aim was to identify whether
circulating miRNAs, added to clinical and biochemical markers
(HbA1c, glucose, insulin, glucose after 2 hr of oral glucose tolerance
test [OGTT], hepatic insulin resistance index [HIRI], insulinogenic
index [IGI], insulin sensitivity index [ISI], disposition index [DI],
muscle insulin sensitivity index [MISI], homeostatic model assess-
ment-insulin resistance [HOMA-IR], and FINDRISC), would have
the potential to predict new incident cases of T2DMmore accurately.
RESULTS
Baseline Characteristics of the Patients
In the present work, from the full Coronary Diet Intervention with
Olive Oil and Cardiovascular Prevention (CORDIOPREV) study
population (1,002 patients), we included the 462 patients who at base-
line had not been clinically diagnosed with T2DM.
At baseline, we observed higher values of waist circumference, body
mass index (BMI), triglycerides (TGs), glucose, insulin, and HbA1c
in the subgroup of patients who developed T2DM in a median
follow-up of 60 months (Incident-T2DM group), compared with pa-tients who did not develop T2DM (non-T2DM group) (all, p < 0.05).
Moreover, our results showed lower baseline ISI, IGI, and DI and
higher baseline HIRI and HOMA-IR values in the Incident-T2DM
subgroup than in the non-T2DM group (all, p < 0.05). Conversely,
we did not observe any differences in the baseline MISI (Table 1).
Bibliographic Identification of T2DM-Related Circulating
miRNAs
Our bibliographic search of miRNAs associated with insulin sensi-
tivity, insulin secretion and growth, and proliferation of beta cell
yielded 24 miRNAs. When we measured the levels of miRNAs at
baseline of the study (day 0 before dietary intervention), 17 were de-
tected in the plasma of at least 80% of the patients, 4 were detected in
less than 80% of the samples, and 3 were not detected at all in the
plasma samples. (Table S1).
Multivariate Analysis by PCA and OPLS-DA
Whereas principal-components analysis (PCA) did not yield statisti-
cally signiﬁcant results, the orthogonal partial least-squares discrim-
inant analysis (OPLS-DA) showed differences between Incident-
T2DM and non-T2DM (Q2 = 0.239; R2y = 0.270 and R2x = 0.575).
Moreover, the variables importance projection (VIP) analysis identi-
ﬁed 9 miRNAs (miR-9, miR-28-3p, miR-29a, miR-30a-5p, miR-103,
miR-126,miR-150,miR-223, andmiR-375) with VIP scores > 1, which
supports their relevance in differentiating between Incident-T2DM
and non-T2DM patients (Figure 1).
Baseline Levels of Circulating miRNAs
We observed that the baseline plasma levels of 9 miRNAs (miR-9,
miR-15a, miR-28-3p, miR-29a, miR-103, miR-223, miR-126, miR-
145, and miR-375) were signiﬁcantly lower in Incident-T2DM pa-
tients than in non-T2DM patients. In contrast, the baseline plasma
levels of 2 miRNAs (miR-30a-5p and miR-150) were signiﬁcantly
higher in Incident-T2DM as compared with non-T2DM patients.
No signiﬁcant differences between groups were found in the plasma
levels of miR-7, miR-10, miR-182, and miR-320 (Table 1).
Baseline Circulating Levels of miRNAs According to the Year of
T2DM Diagnosis
From the 462 subjects included in this study, a total of 107 subjects
developed T2DM (Incident-T2DM group) during the follow-up
period, of whom 43 were diagnosed after the ﬁrst year of follow-up,
24 in the second year, 11 in the third year, 19 in the fourth year,
and 10 in the ﬁfth year. The remaining group of subjects (355 sub-
jects) did not develop the disease (non-T2DM group). To evaluate
the inﬂuence of the time before the T2DM diagnosis on the predictive
value of each baseline miRNA to identify individuals at high risk of
developing the disease, we analyzed the baseline circulating levels of
miRNAs in each subgroup of patients according to the year in which
the diagnosis of T2DM took place, as compared with patients who did
not develop T2DM. Overall, we observed lower baseline circulating
levels of miR-103, miR-28-3p, miR-9, and miR-29a in subjects diag-
nosed with T2DM in the ﬁrst 3 years of follow-up and higher levels
of miR-30a-5p and miR-150 in subjects diagnosed with T2DM inMolecular Therapy: Nucleic Acids Vol. 12 September 2018 147
Table 1. BaselineCharacteristics andCirculatingmiRNA Levels of SubjectsWhoDidNot Develop T2DM (Non-T2DM) versus SubjectsWhoDeveloped T2DM
(Incident-T2DM) after the Follow-up Period
Variable Non-T2DM Group Incident-T2DM Group p Value miRNAs Non-T2DM Group Incident-T2DM Group p Value q- Value
n 355 107 – – – – – –
Age (years) 57 ± 0.5 59 ± 0.9 0.171 miR-103 103.9 ± 4.5 62.1 ± 4.8 <0.001 <0.001*
Waist circumference (cm) 101.7 ± 0.6 105.3 ± 1.1 0.003* miR-107 1.70 ± 0.09 1.65 ± 0.17 0.810 0.853
BMI (kg/m2) 29.9 ± 0.2 31.4 ± 0.5 0.002* miR-223 79.0 ± 3.5 56.7 ± 3.6 0.016 0.032*
TG (mg/dL) 119.5 ± 3.2 132.6 ± 6.6 0.041* miR-29a 68.1 ± 2.1 54.8 ± 4.0 <0.001 <0.001*
Total cholesterol (mg/dl) 160.6 ± 1.6 164.9 ± 3.4 0.288 miR-28-3p 185.9 ± 9.6 101.1 ± 8.8 <0.001 <0.001*
c-LDL (mg/dL) 91.1 ± 1.3 93.4 ± 2.7 0.473 miR-126 31.4 ± 1.6 18.8 ± 1.4 <0.001 <0.001*
c-HDL (mg/dL) 44.6 ± 0.5 43.5 ± 1.0 0.290 miR-145 5.10 ± 0.27 4.11 ± 0.43 0.013 0.021*
Apo A1 (mg/dL) 133.1 ± 1.2 135.2 ± 2.3 0.283 miR-150 0.69 ± 0.04 1.07 ± 0.09 <0.001 <0.001*
Apo B (mg/dL) 71.8 ± 1.0 76.3 ± 1.8 0.035* miR-15a 2.70 ± 0.13 2.08 ± 0.28 <0.001 <0.001*
hs-CRP (mg/L) 2.51 ± 0.19 2.88 ± 0.29 0.031* miR-182 58.7 ± 2.7 59.1 ± 4.9 0.7670 0.7887
Glucose (mg/dL) 92.6 ± 0.5 96.2 ± 1.1 0.002* miR-30a-5p 25.6 ± 1.3 35.2 ± 2.5 <0.001 <0.001*
HbA1c (%) 5.8 ± 0.02 6.0 ± 0.03 <0.001* miR-320 23.2 ± 0.9 24.0 ± 1.4 0.434 0.419
Insulin (mU/L) 8.33 ± 0.31 10.51 ± 0.66 0.007* miR-375 20.9 ± 0.9 15.4 ± 1.1 0.013 0.020*
HIRI 1052 ± 37 1313 ± 90 0.002* miR-7 6.38 ± 0.33 6.88 ± 0.58 0.398 0.425
MISI ( 102) 2.10 ± 0.11 1.89 ± 0.16 0.369 miR-9 2.03 ± 0.15 0.93 ± 0.18 <0.001 0.002*
DI 1.01 ± 0.03 0.77 ± 0.04 <0.001* – – – – –
ISI 4.30 ± 0.14 3.27 ± 0.18 <0.001* – – – – –
IGI 1.14 ± 0.06 0.88 ± 0.07 0.025* – – – – –
HOMA-IR 2.58 ± 0.09 3.23 ± 0.22 0.002* – – – – –
Values expressed as mean ± SE. BMI, body mass index; c-HDL, high-density lipoprotein; c-LDL, low-density lipoprotein; TG, triglycerides; Apo A1, Apolipoprotein A1; Apo B,
Apolipoprotein B; hs-CRP, high-sensitivity C-reactive protein; HbA1c, glycosylated hemoglobin; HIRI, hepatic insulin resistance index; MISI, muscle insulin sensitivity index; ISI,
insulin sensitivity index; IGI, insulinogenic index; DI, disposition index; HOMA-IR, homeostasis model assessment-insulin resistance. Variables were calculated using one-way
ANOVA through SPSS (now PASW Statistic for Windows, version 21.0) (IBM, Chicago, IL, USA). For data that did not ﬁt the normal distribution, the Mann-Whitney U test
was performed. *p < 0.05 in one-way ANOVA or after the false discovery rate (FDR) correction.
Molecular Therapy: Nucleic Acidsthe ﬁrst year of follow-up, compared with subjects diagnosed in later
years and with the non-T2DM group (Figure 2).
Relationship between miRNA Plasma Levels and Insulin
Sensitivity/Resistance and Beta Cell Function Indexes
We studied the relationship between the plasma levels of the 9
miRNAs, identiﬁed by OPLS-DA, and the insulin sensitivity, beta
cell function, and the insulin resistance of peripheral tissues,
such as liver and muscle, by lineal regression methods, adjusted by
age, gender, BMI, TGs, and high-density lipoprotein cholesterol
(c-HDL). We observed that the ISI, DI, and IGI were related with
the plasma levels of miR-126, miR-103, and miR-150, respectively.
Moreover, we also observed a relationship between miRNAs and
fasting glucose (miR-28-3p, miR-30a-5p, miR-103, miR-126, and
miR-150) and HbA1c (miR-28-3p, miR-103, miR-223, and miR-375)
(Table 2).
Received Operating Characteristic Curve Analysis
To evaluate the potential of miRNA plasma levels as a predictive
biomarker of T2DM, the accuracy, sensitivity, and speciﬁcity were
compared in 10 different models of received operating characteristic
(ROC) analysis. We built models including all the miRNAs, measured148 Molecular Therapy: Nucleic Acids Vol. 12 September 2018together with the classic parameters (fasting glucose, 2-hr glucose,
and HbA1c), beta cell function and insulin sensitivity/resistance in-
dexes (IGI, ISI, DI, HIRI, and MISI), and the FINDRISC5 (Table S2).
First, we included the full miRNA dataset (15 miRNAs) as input vari-
ables in the model, and we obtained an area under the curve (AUC) =
0.849 (95% conﬁdence interval [CI] = 0.808–0.889). Further, we
reduced the number of miRNAs included in the model according
to the VIP score in the OPLS-DA. Thus, a model built including
the 9 miRNAs with a VIP value of over 1 (miR-9, miR-28-3p, miR-
29a, miR-30a-5p, miR-103, miR-126, miR-150, miR-223, and miR-
375) yielded an only slightly reduced signiﬁcance in the model
AUC = 0.818 (95% CI = 0.771–0.864), as compared with the full 15
miRNA dataset.
Interestingly, the classic parameters, such as fasting glucose, insulin,
2-hr glucose (OGTT), and HbA1c, together with the insulin sensi-
tivity indexes ISI, DI, IGI, HIRI, MIRI, HOMA-IR, and HOMA-
beta yielded an AUC of 0.769 (95% CI = 0.713–0.826). In addition,
the FINDRISC showed an AUC of 0.610 (95%CI = 0.550–0.671) (Fig-
ure 3A), which did not improve when we included insulin sensitivity
indexes in the model AUC = 0.765 (95% CI = 0.709–0.820).
Q2= 0.239
R2y=0.270
R2x=0.575
miRNAs VIP score
hsa-miR-150 1.57283 
hsa-miR-103 1.52393 
hsa-miR-28-3p 1.48090 
hsa-miR-126 1.33097 
hsa-miR-9 1.14448 
hsa-miR-30a-5p 1.09448 
hsa-miR-223 1.04366 
hsa-miR-375 1.04034 
hsa-miR-29a 1.00829 
hsa-miR-15a 0.62923 
hsa-miR-145 0.29040 
hsa-miR-7 0.23827 
hsa-miR-320 0.05359 
hsa-miR-182 0.04412 
hsa-miR-107 0.03950 
Figure 1. Orthogonal Partial Least-Squares Discriminant Analysis
Orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to
compare miRNA levels at baseline in order to analyze the differences between Inci-
dent-T2DM (gray circle) and non-T2DM patients (black circle) during follow-up. The
quality of the models obtained by PCA and OPLS-DA was assessed by interrogation
of the R2 and Q2 parameters. The miRNAs with VIP score > 1 were considered
important for differentiating between groups (table within the image). Data were
processed using SIMCA-P+ (version 14.0.0.1359; Umetrics, Umea, Sweden).
www.moleculartherapy.orgTo obtain an implemented miRNA-based model, we combined the
dataset of 9 miRNAs with the HbA1c, which was the classic clinical
parameter with greater weight in the Average Importance of Variables
classiﬁcation. Thus, the HbA1c showed an AUC of 0.676 (95% CI =
0.605–0.737), which improved after inclusion of the 9 miRNAs
(AUC of 0.834; 95% CI = 0.790–0.878, sensitivity = 0.766, speciﬁcity =
0.809, and accuracy = 80.0%) (Figure 3A). In addition, the ROC anal-
ysis showed 3 miRNAs (miR-9, miR-28-3p, and miR-29a) with the
highest differentiation power from the Average Importance of Vari-
ables classiﬁcation, followed by HbA1c and miR-150 (Figure 3B).
Additionally, we built a model including the clinical parameters in
the assessment of T2DM risk without miRNAs (fasting glucose,2-hr glucose in OGTT, HbA1c, age, gender, BMI, c-HDL, TGs,
diet, and waist circumference) showing an AUC = 0.7354 (Figure 3A).
Moreover, when we included the FINDRISC5 together with the data-
set of the 9miRNAs andHbA1c, we did not improve the model (AUC
of 0.829; 95% CI = 0.785–0.874, sensitivity = 0.796, speciﬁcity = 0.774,
and accuracy = 77.9%), as compared with the one that included the
dataset of 9 miRNAs and HbA1c.
Also, the AUCs of all models were compared using the DeLong test,
and we observed a signiﬁcant difference between the model based on
clinical parameters without miRNAs (fasting glucose, 2-hr glucose in
OGTT, HbA1c, age, gender, BMI, c-HDL, TGs, diet, and waist
circumference) and the model based on 9 miRNAs and HbA1c
(adjusted by age, gender, BMI, c-HDL, TGs, diet, and waist circum-
ference) (p = 0.01002).
Internal validation by bootstrap resampling of the original set (1,000
randomized samples) in the best model (9miRNAs +HbA1c) showed
a degree of over-optimism of 0.03, which represents the deviation
from the mean SE in estimation of these 1,000 samples (bootstrapped
AUC ROC = 0.796).
Cox Regression Analysis
To test the T2DM-predictive value of miRNAs by the Cox regression
analysis, we selected those with the highest VIP values in the OPLS-
DA multivariate analysis: 9 miRNAs (miR-9, miR-28-3p, miR-29a,
miR-30a-5p, miR-103, miR-126, miR-150, miR-223, and miR-375;
Figure 1).
To perform the Cox regression analysis, we categorized subjects in
tertiles according to the plasma levels for each miRNA as follows:
low baseline plasma levels (T1), medium baseline plasma levels
(T2), and high baseline plasma levels (T3). We compared the hazard
ratio (HR) between T1 and T3 for each studied miRNA.We observed
that low baseline plasma levels (T1) in 4 miRNAs (miR-9,miR-28-3p,
miR-29a, andmiR-103) and high plasma levels (T3) in 2 of 9 miRNAs
(miR-30a-5p andmiR-150) were associated with a high risk of T2DM
development (HR T1 versus T3R 2.5) (Table 3).
Accordingly, to study the accumulative predictive value of the
six miRNAs together, we included these six miRNAs with
HR T1 versus T3R 2.5 and performed a Cox regression multi-miRNA
analysis (Figure 4).
Next, we categorized patients according to the levels of these six
miRNAs as follows: C1 category was composed of patients with low
levels in at least three of the four downregulated miRNAs (miR-9,
miR-28-3p, miR-29a, and miR-103) and high levels in at least one
of the 2 upregulated miRNAs (miR-150 and miR-30a-5p) (n = 46);
C3 category was composed of patients with high levels in at least three
of the four downregulated miRNAs and low levels in at least one of
the two upregulated miRNAs (n = 32); and, ﬁnally, C2 was made
up of patients with an intermediate miRNA deregulation proﬁleMolecular Therapy: Nucleic Acids Vol. 12 September 2018 149
Figure 2. Circulating miRNA Levels at Baseline
According to the Time Point at which Patients Were
Diagnosed with T2DM
Data are represented as the mean ± SEM and corre-
spond to the one-way ANOVA (in gray, subjects who
developed T2DM [Incident-T2DM] and in white, subjects
who did not develop T2DM [Non-T2DM]). The differences
between groups were evaluated by Mann-Whitney U test.
*p < 0.05.
Molecular Therapy: Nucleic Acids(n = 356). We therefore obtained an HR between C1 and C2 of 2.34
(95% CI = 0.74–7.42) and an HR between C1 and C3 of 11.68 (95%
CI = 3.56–38.34). Likewise, when we adjusted the Cox regression
analysis by age, gender, BMI, diet, HbA1c, waist circumference,
TGs, c-HDL, IGI, HOMA-IR, and DI, we observed a HR for C1 versus
C2 of 2.66 (95% CI = 0.64–11.07) and for C1 versus C3 of 11.27 (95%
CI = 2.61–48.65) (Figure 5).
To compare ourmiRNA-based predictivemodel with the FINDRISC,5
we categorized subjects into tertiles, according to the FINDRISC of our
study as follows: low FINDRISC (T1), medium FINDRISC (T2), and
high FINDRISC (T3). Next, we performed the Cox regression analysis
and observed anHR between tertiles of FINDRISC T1 and T2 of 1.895
(95% CI = 1.131–3.174) and T1 and T3 of 2.362 (95% CI = 1.410–
3.957) (Figure S1).
DISCUSSION
Our study showed that plasma levels of 9 of the 17 miRNAs selected
with detectable levels at baseline of the study in most of our subjects
were signiﬁcantly associated with glucose metabolism and type 2 dia-
betes risk. These 9 miRNAs, in combination with HbA1c plasma
levels, were able to differentiate between the patients who developed
type 2 diabetes (Incident-T2DM) after a median follow-up of
60 months and those patients who did not develop the disease
(Non-T2DM), with an AUC in the model of 0.834. The Cox regres-
sion analysis showed that patients with low miR-103, miR-28-3p,
miR-29a, andmiR-9 and highmiR-30a-5p andmiR-150 plasma levels
were at higher risk of developing T2DM.
The relevance of the T2DM prevalence ﬁgures lies in the fact that sub-
jects with T2DM have higher cardiovascular morbidity and mortality
compared with non-diabetic subjects.29 In addition, patients with
acute myocardial infarction (AMI) and T2DM have a considerably
higher risk of developing a new cardiovascular event than those
without T2DM.30 It is, therefore, very important to identify early150 Molecular Therapy: Nucleic Acids Vol. 12 September 2018on individuals with a higher risk of developing
T2DM, in order to prevent the onset of the dis-
ease by using powerful therapies and efﬁciently
controlling the associated cardiovascular risk
factors.
Nowadays, the standard tools for identifying
patients with a risk of T2DM include HbA1cand scores such as the FINDRISC. However, these tools are not
able to effectively predict the disease development. Previous studies
have revealed a number of limitations of HbA1c as a diagnostic test
in comparison with FPG in the elderly, in which the lower sensitivity
and speciﬁcity of HbA1c was demonstrated.12,13 Moreover, it has
recently become evident that FINDRISC is not universally applicable
among all ethnic groups and populations.31,32
In addition, current evidence indicates that the blood miRNA proﬁle
may change under different pathophysiological conditions, such as
cancer,33 cardiovascular diseases,34 and type 2 diabetes.35
In fact, two previous studies have related miRNA plasma levels with
the grade of insulin resistance. One of them by Shah et al. identiﬁed 18
circulating miRNAs associated with plasma insulin and HOMA-IR
levels,28 of which 4 were also identiﬁed as being deregulated in the
study by Zampetaki et al., who identiﬁed 13 miRNAs associated
with the incidence of T2DM.25 In our study, 9 miRNAs were identi-
ﬁed as being important in the prediction model for T2DM, but only
one matched with those identiﬁed by Zampetaki et al.25 and by Shah
et al.28, suggesting that the differences in the phenotype between
populations seem to be important in the deregulation of the miRNA
proﬁle associated with a pathological condition, such as glucose
homeostasis.
In terms of T2DM prediction, the study by Zampetaki et al.25 inves-
tigated miRNA plasma levels before the diagnosis of T2DM, which
identiﬁed 5 miRNAs (miR-15a, miR-28-3p, miR-29b, miR-126, and
miR-223) associated with the incidence of T2DM. Nevertheless, the
small number of incident cases (n = 19) reported in that study pre-
cluded the more extensive statistical predictive analysis that we
have carried out in our study (ROC and Cox regression analyses).
In contrast, our study included all 462 non-diabetic patients of the
CORDIOPREV at baseline of the study, of whom 107 developed
T2DM in a median follow-up of 60 months, and the statistical
Table 2. Relationship between Circulating Levels of miRNAs and T2DM-Related Parameters
hsa-miR103 hsa-miR28-3p hsa-mir-126 hsa-miR150 hsa-miR30a-5p hsa-miR9 hsa-miR375 hsa-miR223 hsa-miR29a
HbA1c (%)
r2 0.112 0.122 0.017 0.070 0.056 0.049 0.125 0.091 0.060
p 0.014* 0.008* 0.369 0.085 0.134 0.168 0.007* 0.037* 0.121
Glucosa (mg/dL)
r2 0.129 0.112 0.099 0.107 0.109 0.082 0.000 0.039 0.019
p 0.006* 0.014* 0.026* 0.018* 0.016* 0.054 0.497 0.220 0.354
Insulina (mU/L)
r2 0.011 0.034 0.041 0.027 0.031 0.008 0.003 0.030 0.006
p 0.413 0.250 0.209 0.300 0.274 0.436 0.478 0.276 0.455
HOMA-IR
r2 0.016 0.026 0.013 0.010 0.001 0.059 0.027 0.006 0.040
p 0.380 0.306 0.396 0.424 0.490 0.123 0.301 0.452 0.217
MISI
r2 0.080 0.025 0.037 0.012 0.046 0.069 0.015 0.048 0.023
p 0.059 0.313 0.236 0.409 0.182 0.089 0.385 0.172 0.323
IGI
r2 0.053 0.016 0.015 0.102 0.021 0.080 0.031 0.013 0.030
p 0.148 0.377 0.382 0.022* 0.340 0.060 0.269 0.398 0.280
ISI
r2 0.029 0.077 0.102 0.041 0.000 0.015 0.008 0.078 0.003
p 0.283 0.065 0.023* 0.213 0.499 0.444 0.441 0.062 0.478
DI
r2 0.096 0.076 0.070 0.047 0.045 0.054 0.012 0.048 0.062
p 0.030* 0.068 0.083 0.177 0.189 0.148 0.409 0.174 0.113
HIRI
r2 0.016 0.033 0.024 0.021 0.004 0.063 0.024 0.010 0.042
p 0.376 0.228 0.316 0.340 0.467 0.328 0.319 0.422 0.208
HbA1c, glycosylated hemoglobin; GLU, glucose; HOMA-B, homeostasis model assessment-beta cell function; HOMA-IR, homeostasis model assessment-insulin resistance; MIRI,
muscle insulin resistance index; IGI, insulinogenic index; ISI, insulin sensitivity index; DI, disposition index; HIRI, hepatic insulin resistance index. Relationship was evaluated through
a linear regression analysis adjusted by age, gender, body mass index (BMI), triglycerides (TG), and high-density lipoproteins (c-HDL), using SPSS (now PASW Statistic for Windows,
version 21.0) (IBM, Chicago, IL, USA). *p < 0.05 in the linear regression analysis.
www.moleculartherapy.orgmodeling (ROC and Cox regression models) allowed us to predict the
onset of T2DM. In addition, in our study we followed ADA diagnosis
criteria,26 whereas the study by Zampetaki et al.25 followed the World
Health Organization guidelines, which do not take into account
plasma levels of HbA1c as diagnosis criteria for diabetes and, there-
fore, did not produce a very accurate diagnosis.
The ROC analysis showed that HbA1c levels together with the set of 9
miRNAs were able to differentiate between Incident-T2DM and non-
T2DM patients (AUC 0.834), and, furthermore, the model was more
accurate than when only HbA1c (AUC 0.676) was used. In fact,
the plasma levels of these 9 circulating miRNAs differentiate better
between groups (Incident-T2DM versus non-T2DM) than the
FINDRISC, on the basis of an AUC of 0.818 (9 miRNA plasma levels
as input data) versus 0.610 obtained with the FINDRISC alone. It is
worth noting that adding the FINDRISC to the 9-miRNA models
(model 1: 9 miRNAs target + FINDRISC and model 2: 9 miRNAs
target + FINDRISC + HbA1c) did not improve the accuracy in
discriminating between the two groups of patients (AUC = 0.812
and AUC = 0.829, respectively).
Our results are in line with a recently published pilot cross-sectional
study in which 8 miRNAs were able to discriminate between healthy
people (n = 27), prediabetic patients (n = 12), type 1 diabetes patients
(n = 16), and type 2 diabetes patients (n = 31),36 supporting the idea
that miRNA plasma levels could be used as disease biomarkers. How-ever, the study by Syehan et al.36 was performed in T2DM patients
without a follow-up period, and, therefore, incidence was not
analyzed, which means this study has no predictive value. More rele-
vantly, our prospective study has shown the predictive value of
measuring plasma miRNAs as biomarkers before T2DM develop-
ment in patients at risk. Moreover, we studied different predictive
models in a much larger population, including miRNAs for the ﬁrst
time as biomarkers. When these were added to the classic parameters,
such as fasting glucose, insulin, 2-hr glucose (OGTT), HbA1c, insulin
sensitivity indexes, and the FINDRISC, it allowed us to assess the risk
of developing T2DM over the following 5 years.
Overall, after the multi-miRNA Cox regression analysis, we showed
that the plasma levels of six miRNAs (miR-9, miR-28-3p, miR-29a,
miR-103,miR-30a-5p, andmiR-150) could potentially be used as pre-
dictive biomarkers, which is supported by their involvement in mech-
anisms related with the development of T2DM.
Circulating miRNAs are considered as a novel class of signaling mol-
ecules mediating intercellular communication,14 and the blood
miRNA proﬁle may change under different pathophysiological condi-
tions, which allows for their potential use as biomarkers in certain dis-
eases such as T2DM.25,33,35 However, circulating and intracellular
miRNA levels may not match because, after the intracellular expres-
sion, miRNAsmay be released,37 and, therefore, a reduction in release
could lead to intracellular accumulation but low plasma levels.Molecular Therapy: Nucleic Acids Vol. 12 September 2018 151
Figure 3. ROC Analysis and Classification by Average Importance of
Variables Included in a ROC Model Based on miRNAs and HbA1c
(A) The comparison among the AUC of ROC curves of three models: red line,
miRNA- and HbA1c-based model; green line, clinical parameters model; blue line,
FINDRISC model. (B) The average importance classification of the variables
included in the ROC curve can be seen. Non-T2DM = 0; Incident-T2DM = 1.
Analysis was carried out by MetaboAnalyst 3.0.
Table 3. Hazard Ratio Observed after Cox Regression Analysis for Each
miRNA Included in the ROC Curve
miRNA
HR T1 versus T1
(95% CI)
HR T1 versus T2
(95% CI)
HR T1 versus T3
(95% CI)
miR-150 1 (ref) 2.40 (1.30–4.43) 3.98a (2.21–7.17)
miR-103 1 (ref) 2.07 (1.15–3.71) 3.20a (1.85–5.55)
miR-28-3p 1 (ref) 2.83 (1.49–5.30) 4.45a (2.40–8.24)
miR-126 1 (ref) 1.82 (1.05–3.16) 2.28 (1.34–3.90)
miR-9 1 (ref) 0.99 (0.51–1.92) 3.95a (2.34–6.65)
miR-30a-5p 1 (ref) 1.37 (0.79–2.40) 2.53a (1.53–4.18)
miR-223 1 (ref) 2.56 (1.47–4.47) 1.90 (1.07–3.35)
miR-375 1 (ref) 1.78 (1.05–3.00) 1.54 (0.90–2.63)
miR-29a 1 (ref) 1.73 (0.97–3.07) 2.51a (1.46–4.33)
amiRNAs selected for multiple COX regression analyses.
Molecular Therapy: Nucleic AcidsAdditionally, previous studies demonstrated the miRNA levels in the
T2DM-diagnosed status, in contrast with our study in which we eval-
uated the proﬁle of miRNAs years before disease development and
diagnosis. In fact, previous evidence has shown that upregulation of
miR-29a in INS-b cell mediates b cell dysfunction and could
contribute to the progression from impaired glucose tolerance to
type 2 diabetes.38 Moreover, the inhibition of miR-103 leads to
improved glucose homeostasis and insulin sensitivity in obese
mice39 and an anti-inﬂammatory effect mediated by Cav1.40 In addi-
tion, the overexpression ofmiR-9 causes a decrease in glucose-stimu-
lated insulin exocytosis by diminishing the expression of the
transcription factor Onecut2, which represses the expression of gran-
ulophilin and negatively regulates insulin release.41
In the last few years, miRNA plasma levels have been shown to be use-
ful as biomarkers for cardiovascular events34 and cancer.33 However,
to the best of our knowledge, no studies have yet focused on the use of
miRNAplasma levels as predictive biomarkers of T2DMdevelopment152 Molecular Therapy: Nucleic Acids Vol. 12 September 2018by combining a sample size large enough to obtain reliable results and
robust statistical models. Thus, our study demonstrated for the ﬁrst
time that plasma levels of miR-9, miR-28-3p, miR29a, miR-103,
miR-30a-5p, and miR-150 are also powerful predictive biomarkers
that can discriminate between Incident-T2DM and non-T2DM pa-
tients. More importantly, our results showed that the alteration in
miRNA levels precedes the development of T2DM by 3 years, and,
therefore, our model has a predictive power in this period of time.
Nonetheless, our study has limitations. One limitation lies in the fact
that we carried out a focused bibliographic search of the miRNAs
associated with insulin sensitivity, insulin secretion and growth,
and proliferation of beta cells, which meant that any potential
miRNAs whose implication with T2DM has not yet been described
were not included in our model. In addition, T2DM prevention was
not the primary endpoint of the CORDIOPREV trial, but it was a sec-
ondary analysis conducted in the subgroup of cardiovascular patients
without T2DM at baseline. Finally, the study included a large number
of elderly patients with AMI, which limits our ﬁndings to people with
these characteristics and precludes generalization to healthy individ-
uals. In line with this, futures studies should focus the validation of
this study on another population. Although diabetes prediction is
very important as patients with AMI and T2DM have a considerably
higher risk of developing a new cardiovascular event than those
without T2DM,30 the validation in a cohort without cardiovascular
disease and closer to the general population would allow us to adapt
this method to the general population.
In conclusion, our results suggest that miRNA plasma levels added to
HbA1c could become a valuable new tool for assessing the early risk
of type 2 diabetes in clinical practice to prevent disease development.
MATERIALS AND METHODS
Study Subjects
Thisworkwas conductedwithin the framework of theCORDIOPREV
study. The rationale, methods, and baseline characteristics have been
reported by Delgado-Lista et al.,42 and they are also provided in
Figure 4. Disease-free Probability Analysis through
a Cox Regression Model with the Six-miRNA Target
Data represent circulating levels for each miRNA by ter-
tiles, low levels (T1), medium levels (T2), and high levels
(T3). The analysis was carried out using SPPS (now PASW
Statistic for Windows, version 21.0) (IBM, Chicago, IL,
USA) and adjusted by diet, age, gender, BMI, TGs, c-HDL,
HbA1c, and waist circumference.
www.moleculartherapy.orgClinicalTrials.gov (NTC00924937). Brieﬂy, the CORDIOPREV study
is an ongoing prospective, randomized, single blind, controlled dietary
intervention trial in 1,002 patients with coronary heart disease (CHD),
high cardiovascular risk, aged between 20 and 75 years old, who had
their last coronary event more than 6 months prior to enrollment
and had no severe diseases or a life expectancy of less than 5 years.
In addition to conventional treatment for CHD, the subjects were ran-
domized into twodifferent dietarymodels (Mediterranean and low-fat
diets). The intervention phase is still in progress and will have a me-
dian follow-up of 7 years. The patients were recruited fromNovember
2009 to February 2012, mostly at the Reina Soﬁa University Hospital
(Córdoba, Spain), but patients from other hospital centers from the
Córdoba and Jaen provinces were also admitted. Written consent
was obtained from all the subjects prior to recruitment, and the study
protocol and all amendments were approved by the Ethics Committee
of Hospital Reina Soﬁa, all of which follow the Helsinki Declaration
and good clinical practices.
In the present work, all the subjects (n = 462) who had not been clin-
ically diagnosed with T2DM at baseline in the CORDIOPREV-DIAB
study were included.43 Of this group, 43 subjects were diagnosed as
having T2DM after the ﬁrst year of follow-up, 24 in the second
year, 11 in the third year, 19 in the fourth year, and 10 in the ﬁfth
year, for a total of 107 subjects who developed T2DM (Incident-
T2DM), according to all the ADA diagnosis criteria,26 evaluated on
the basis of glucose tolerance tests performed each year during the
median follow-up of 60 months (Figure S2). Of the 462 subjects
included in the current work, 216 were randomized to consume a
low-fat high-complex carbohydrate diet (LFHCC diet) and 246 to
consume a Mediterranean diet (Med diet). The differences between
diets were evaluated by Chi-square test, and we observed no statistical
signiﬁcance (Chi2 = 1.948; p = 0.163). The baseline characteristics of
the subjects in the study are shown in Table 1.Molecular TherapBiochemical Measurements of Metabolic
Parameters
Venous blood from the participants was
collected in tubes containing EDTA after a
12-hr overnight fast. Lipid variables were as-
sessed with the DDPPII Hitachi modular auto
analyzer (Roche, Basel, Switzerland) using
speciﬁc reagents (Boehringer-Mannheim, Man-
nheim, Germany). Measurements of total
cholesterol (TC) and TG levels were performed
by colorimetric enzymatic methods,44,45 c-HDLwas measured by colorimetric assay,46 and low-density lipoprotein
(c-LDL) concentration was calculated by the Friedewald equation, us-
ing the following formula: c-LDL = CT  (c-HDL + TG/5). Glucose
measurements were performed using the hexokinase method. The
hs-C-Reactive Protein (hs-CRP) was determined by high-sensitivity
ELISA (BioCheck, Foster City, CA, USA). Plasma insulin concentra-
tions were measured by microparticle enzyme immunoassay (Abbott
Diagnostics, Matsudo-shi, Japan). Non-esteriﬁed fatty acid concen-
trations were measured by enzymatic colorimetric assay (Roche Diag-
nostics, Penzberg, Germany). ApoA-1 and ApoB concentrations were
determined by immunoturbidimetry.
Estimation of IR, Insulin Secretion, and Beta Cell Function
Indexes and FINDRISC
Before starting the test, the patients had fasted (from food and drugs)
for 12 hr, and they were asked to refrain from smoking during the fast-
ing period and from alcohol intake during the preceding 7 days. They
were also asked to avoid strenuous physical activity the day before the
test was given. At 8:00 a.m., the patients were admitted into the labo-
ratory to perform the OGTT (75 g dextrose monohydrate in 250 mL
water, NUTER. TEC GLUCOSA 50), and 0-, 30-, 60-, and 120-min
samplingwas performed to establish plasma glucose and insulin levels.
The Matsuda ISI was calculated from the OGTT using the following
formula: ISI = 10.000O O([fasting plasma glucose  fasting plasma
insulin]  [mean glucose in OGTT  mean insulin in OGTT]).47
HOMA-IR was calculated as previously described by Song et al.48 In-
sulin secretion was measured by the IGI as follows: IGI = [30 min in-
sulin  fasting insulin (pmol/L)]/[30 min glucose  fasting glucose
(mmol/L)].49 Beta cell function was estimated by calculating the DI
as follows: DI = ISI  [AUC30 min insulin/AUC30 min glucose],
where AUC30 min is the AUC between baseline and 30 min of the
OGTT for insulin (pmol/L) and glucose (mmol/L) measurements,y: Nucleic Acids Vol. 12 September 2018 153
Figure 5. Disease-free Analysis through a Cox Regression Model Based on
Multi-miRNAs, Including miR-103, miR-28-3p, miR-29a, miR-9, miR-150,
and miR-30a-5p
The data represent circulating levels of all six miRNAs together; subjects were,
therefore, classified into three categories as follows: C1 category was composed of
patients with low levels in at least three of the four downregulated miRNAs (miR-9,
miR-28-3p, miR-29a, and miR-103) and high levels in at least one of the 2 upre-
gulatedmiRNAs (miR-150 andmiR-30a-5p) (n = 46); C3 category was composed of
patients with high levels in at least three of the four downregulated miRNAs and low
levels in at least one of the two upregulated miRNAs (n = 32); and, finally, C2 was
made up of patients with an intermediate miRNA deregulation profile (n = 356). The
analysis was carried out through SPPS (now PASW Statistic for Windows, version
21.0) (IBM, Chicago, IL, USA) and adjusted by age, gender, BMI, diet, HbA1c, waist
circumference, TGs, c-HDL, IGI, HOMA-IR, and DI.
Molecular Therapy: Nucleic Acidsrespectively, calculated by the trapezoidal method.50 The indices used
to determine tissue-speciﬁc IR were the HIRI and the MISI, which
were calculated as described in previous work by our group,43
following the methods described by Matsuda and DeFronzo47 for
HIRI and Abdul-Ghani et al. for MISI.51 The FINDRISC was calcu-
lated as deﬁned by Lindström et al.5
Isolation of Circulating miRNAs from Plasma Samples
Total RNA was isolated from plasma using the miRNeasy Mini Kit
(QIAGEN, Hilden, Germany). Brieﬂy, venous blood from the partic-
ipants was collected at baseline (day 0 before dietary intervention) in
tubes containing EDTA and centrifuged at 2,000  g for 10 min for
plasma separation from blood cells. Further, 200 mL EDTA-plasma
was mixed with 1 mL Qiazol, incubated for 5 min at room tempera-
ture, and subsequently mixed with 200 mL chloroform. We added
2 mg MS2 RNA carrier (Roche, Mannheim, Germany) before the
chloroform protocol step. The organic and aqueous phases were
separated by centrifugation at 12,000  g for 15 min at 4C. The
aqueous phase was collected and the RNA was precipitated by adding
100% ethanol. The mixture was applied to an miRNeasy Mini spin
column and was centrifuged at 8,000  g for 2 min. Next, 700 mL
RWT buffer was added to the RNeasy MinElute spin column at
8,000  g for 2 min. It was then washed again with 500 mL RPE
buffer and 500 mL 80% ethanol. RNA was eluted in 14 mL RNase-
free water. RNA purity and concentration were evaluated by spectro-154 Molecular Therapy: Nucleic Acids Vol. 12 September 2018photometry using NanoDrop ND-2000 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA).
miRNA Retrotranscription and Preamplification
The miRNA expression study was carried out on 24 miRNAs, which,
based on a bibliographic search, were selected according to their asso-
ciation with insulin sensitivity, insulin secretion, inﬂammation, and
growth and proliferation of beta cells (Table S1). The retrotranscrip-
tion of RNA was carried out using the TaqMan MicroRNA Reverse
Transcription Kit (Life Technologies, Carlsbad, CA, USA). RT mix
contained 2 mL RNA and 3 mL RT custom primer pool in a ﬁnal vol-
ume of 7.5 mL. RT primer pool was customized selecting speciﬁc
primers for our set of target miRNAs in the database (https://www.
thermoﬁsher.com/es/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/mirna-ncrna-taqman-assays.html). Plates were incubated
in the iQ5 thermocycler (Bio-Rad, Hercules, CA, USA) at 16C for
30 min, followed by 42C for 30 min, and ﬁnally at 85C for 5 min.
In this step, the cDNA was stored at 20C for a maximum of
1 week. Then, we prepared a mixture containing 10 mL customized
PreAmp primer pool speciﬁc for our set of target miRNAs and
7.5 mL RT mix and 20 mL TaqMan PreAmp Master Mix (Life Tech-
nologies, Carlsbad, CA, USA) to a ﬁnal volume of 40 mL. Next, the
mixture was incubated in the iQ5 Thermocycler using the following
steps: denaturation at 95C for 10 min, 55C for 2 min, and 72C
for 2 min; 20 cycles of ampliﬁcation for 15 s at 95C and 4 min at
60C per cycle; and ﬁnally incubation at 99.9C for 10 min. The
pre-ampliﬁed products were then diluted with RNase-free water at
a ratio of 1:40 and used for the real-time RT-PCR reactions.
Levels of Circulating miRNAs by Real-Time PCR
We measured the levels of miRNAs at baseline of the study with
the OpenArray platform (Life Technologies, Carlsbad, CA, USA),
following the manufacturer’s instructions. As a normalization
method, we ﬁrst selected the miRNAs that showed the least variability
in their CT values in all samples. For this, we used the NormFinder
Bioinformatic tool (MOMA-Department of Molecular Medicine,
Aarhus University Hospital, Denmark),52 a software extensively
used in expression studies.53,54 The application showed that the
most stable miRNAs were miR-143 and miR-144. Second, we used
the BestKeeper method to calculate the geometric mean of the pair-
wise Ct values (Ct values of miR-143 and miR-144).55 The relative
expression data were analyzed using OpenArray Real-Time qPCR
Analysis Software (Life Technologies, Carlsbad, CA, USA).
PCA and OPLS-DA
Prior to the PCA, the data were normalized into a dataset suitable for
analysis. Applying the procedures of mean-centering and unit vari-
ance (UV) scaling, the data of the miRNA levels were processed using
SIMCA-P+ (version 14.0.0.1359; Umetrics, Umea, Sweden). PCAwas
applied to the dataset and the score plots were visually inspected for
the detection of patterns and outliers. OPLS-DA was used to compare
miRNA levels at baseline, in order to analyze the differences between
Incident-T2DM and non-T2DM patients during follow-up. OPLS-
DA validation was performed by cross-validation (CV) method in
www.moleculartherapy.orgthe SIMCA-P+ software using the default setting, which includes a
procedure of 7-fold cross-validation where the dataset is split into 7
different subsets.56The quality of the models obtained by PCA and
OPLS-DA was assessed by interrogation of the R2 and Q2 parame-
ters.56,57 Next, we selected those miRNAs with higher discriminatory
power between groups from the VIP score obtained in the OPLS-DA
model. The miRNAs with a VIP score > 1 were considered important
for differentiating between groups.
Statistical Analysis
The quantitative data were evaluated for normal distribution by the
Kolmogorov-Smirnov test, with the cutoff for normal distribution
set at p > 0.05. For data that were not normally distributed, we
used the Mann-Whitney U test. The relationship between miRNA
plasma levels and insulin sensitivity/resistance and beta cell function
indexes was evaluated through a linear regression analysis adjusted by
age, gender, BMI, TGs, and c-HDL. We used the Cox proportional
hazard regression analysis to test the potential predictive value of
the miRNAs studied. The level values of each miRNA were catego-
rized by tertiles: low levels (T1), medium levels (T2), and high levels
(T3). The HR in the analysis of each miRNA studied was analyzed
by comparing T1 versus T2 and T1 versus T3. Six miRNAs with
HR T1 versus T3R 2.5 were selected for Cox regression multi-miRNA
analysis. The subjects were, therefore, classiﬁed into three categories:
C1 category was composed of patients with low levels in at least three
of the four downregulated miRNAs (miR-9, miR-28-3p, miR-29a,
and miR-103) and high levels in at least one of the 2 upregulated
miRNAs (miR-150 and miR-30a-5p) (n = 46); C3 category was
composed of patients with high levels in at least three of the four
downregulated miRNAs and low levels in at least one of the two up-
regulated miRNAs (n = 32); and, ﬁnally, C2 was made up of patients
with an intermediate miRNA deregulation proﬁle (n = 356). This
classiﬁcation was called 6miRNAs-variable and was included in the
Cox regression multi-miRNA analysis. The HR in the analysis be-
tween C1 versus C2 and C1 versus C3 was compared. The lineal
regression and Cox regression analyses were adjusted by age,
gender, diet, HbA1c, BMI, TGs, c-HDL, and waist circumference.
p values % 0.05 were considered statistically signiﬁcant. We used
ROC analysis to estimate the AUC, accuracy, speciﬁcity, and sensi-
tivity of the variables for differentiation of Incident-T2DM from
non-T2DM patients. The models were corrected for those covariables
that were allowed, avoiding overestimating information, the set of co-
variables included: diet, age, gender, BMI, c-HDL, TGs, HbA1c, and
waist circumference. For internal validation of the model, the degree
of over-optimism was estimated using bootstrap resampling of the
original set (1,000 randomized samples).
All the statistical analyses were carried out using SPSS (now PASW
Statistic for Windows, version 21.0) (IBM, Chicago, IL, USA).
Additionally, we used MetaboAnalyst 3.0 to classify the variables
included in the ROC model according to the average importance of
variables. Data normalization was performed using the auto-scaling
method, based on mean centered and divided by the SD of each
variable.58,59 The DeLong test was performed to compare the ROCmodels as described in DeLong et al.60 for paired ROC curves using
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